| MET molecular mechanisms and therapies in lung cancer. | |
| | |
MedLine Citation:
|
PMID: 20139696 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The MET tyrosine kinase signaling pathway is upregulated in many cancers, including lung cancer. The pathway normally promotes mitosis, cell motility and cell survival; but in cancer it can also promote cell proliferation, invasion, metastasis and angiogenesis. The activating ligand, hepatocyte growth factor (HGF) is normally secreted by fibroblasts and smooth muscle cells, but can also be produced by tumor cells. MET upregulation in lung cancer is caused by overexpression and mutation. These mutations can vary with ethnicity. MET signaling affects cytoskeletal proteins such as paxillin, which participates in cell adhesion, growth and motility. Therapeutic approaches that block MET signaling are being studied, and include the use of: small interference RNA, Geldanamycin, competitive HGF homologues, decoy receptors and direct MET inhibitors such as K252a, SU11274, PHA665752 and PF2341066. It is hoped that blocking MET signaling may one day become an effective treatment for some lung cancers. |
| | |
Authors:
|
Ryan E Lawrence; Ravi Salgia |
Related Documents
:
|
20440596 - Depression of mad2 inhibits apoptosis and increases proliferation and multidrug resista... 19850036 - Osteopontin induces beta-catenin signaling through activation of akt in prostate cancer... 20546646 - In vivo modulation of 4e binding protein 1 (4e-bp1) phosphorylation by watercress: a pi... 15740016 - Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in huma... 6533096 - Scope and value of bone marrow biopsies in metastatic cancer. 22228146 - Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian can... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2010-01-16 |
Journal Detail:
|
Title: Cell adhesion & migration Volume: 4 ISSN: 1933-6926 ISO Abbreviation: Cell Adh Migr Publication Date: 2010 Jan-Mar |
Date Detail:
|
Created Date: 2010-04-19 Completed Date: 2010-09-09 Revised Date: 2011-07-19 |
Medline Journal Info:
|
Nlm Unique ID: 101469464 Medline TA: Cell Adh Migr Country: United States |
Other Details:
|
Languages: eng Pagination: 146-52 Citation Subset: IM |
Affiliation:
|
Pritzker School of Medicine, University of Chicago Medical Center, University of Chicago, Chicago, IL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Humans Lung Neoplasms / enzymology*, therapy* Proto-Oncogene Proteins c-met / chemistry, metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
5P01HL058064-140009/HL/NHLBI NIH HHS; 5R01CA100750-06/CA/NCI NIH HHS; 5R01CA125541-03/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 2.7.10.1/Proto-Oncogene Proteins c-met |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An up to date look at lung cancer screening.
Next Document: Role of cell cycle regulators in lung carcinogenesis.